HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-release Ketamine (KET01) Study
Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in…
Mech-Mind debuts as Hong Kong’s first ’embodied intelligence eye-brain-hand’ stock
Walking Together with Love, Passing the Torch for Four Decades – Savills Hong Kong Officially Launches New ‘Savills Volunteer Team’
Fashion Hong Kong delivers a sensory surge of urban energy
Formerra Receives 2026 Eaton Supplier Excellence Award
Kincora Announces Exploration Strategy Update: Drilling Planned Across Four Projects